"This is the second of several upcoming patents," Nuwellis CEONestor Jaramillo says of a "significant stride" the company has taken with its Vivian continuous renal replacement therapy device for critically ill children.
The US Patent and Trademark Office has issued a patent for the device, which "demonstrates a significant stride in medical technology specifically targeting fluid overload in children," the company says in a press release.
The features include self-centering fluid bag hangers and density compensation mechanisms that "enhance fluid management accuracy, ease of use, and system reliability," as well as self-sealing access ports and a temperature-adjusting auto-clamp that "ensures secure seals, reducing the risk of leaks and enhancing overall system dependability," per the release.
The Vivian is currently the only CRRT device approved by the FDA for use in children under the age of 5.
The release notes that "these improvements are not merely technical upgrades but also address critical clinical necessities," such as precise fluid management, which is "important and these innovations could minimize potential complications associated with CRRT."
The release also notes that "the introduction of temperature-adjusting auto-clamps to prevent leaks underscores a significant step towards enhancing system reliability, which is paramount in critical care environments."
The
A customized collection of grant news from foundations and the federal government from around the Web.
When Hannah Davis traveled to China to teach English, she noticed how Chinese workers and farmers were often sporting olive green army-style shoes. Those shoes served as her inspiration to create her own social enterprise, Bangs Shoes.